Viewray Inc (NASDAQ:VRAY) insider James F. Dempsey sold 21,615 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $8.97, for a total transaction of $193,886.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Viewray stock traded down $0.18 during midday trading on Friday, reaching $8.64. 860,493 shares of the stock were exchanged, compared to its average volume of 1,097,062. The firm has a fifty day simple moving average of $8.98. The company has a current ratio of 4.28, a quick ratio of 3.21 and a debt-to-equity ratio of 0.47. The stock has a market cap of $891.97 million, a price-to-earnings ratio of -8.82 and a beta of 0.79. Viewray Inc has a 52 week low of $4.86 and a 52 week high of $12.15.
Viewray (NASDAQ:VRAY) last posted its earnings results on Thursday, May 2nd. The company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.12). The firm had revenue of $20.30 million for the quarter, compared to the consensus estimate of $20.40 million. Viewray had a negative return on equity of 71.16% and a negative net margin of 139.82%. The business’s revenue was down 22.5% on a year-over-year basis. During the same period last year, the company posted ($0.11) EPS. As a group, analysts forecast that Viewray Inc will post -1 EPS for the current year.
Several analysts have recently issued reports on VRAY shares. Piper Jaffray Companies started coverage on shares of Viewray in a research report on Tuesday, June 18th. They issued an “overweight” rating and a $15.00 price target on the stock. TheStreet lowered shares of Viewray from a “c-” rating to a “d” rating in a research report on Friday, May 3rd. Cantor Fitzgerald set a $13.00 price target on shares of Viewray and gave the company a “buy” rating in a research report on Tuesday, May 28th. Zacks Investment Research raised shares of Viewray from a “hold” rating to a “buy” rating and set a $9.50 price target on the stock in a research report on Friday, July 5th. Finally, Mizuho reissued a “buy” rating and issued a $12.00 price target on shares of Viewray in a research report on Wednesday, July 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Viewray currently has a consensus rating of “Buy” and an average price target of $12.95.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
See Also: Why is the LIBOR significant?
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.